Table 1.
Baseline patient, lesion, and procedural characteristics in BIO-RESORT and BIONYX trial participants with known diabetes.
| BIO-RESORT patients with diabetes (N = 624) |
BIONYX patients with diabetes (N = 510) |
||||
|---|---|---|---|---|---|
| SES |
RI-ZES |
EES |
SES |
RO-ZES |
|
| Patients | N = 211 | N = 210 | N = 203 | N = 250 | N = 260 |
| Age (years) | 67.1 ± 9.6 | 65.5 ± 10.9 | 66.7 ± 9.6 | 66.0 ± 10.9 | 66.9 ± 9.7 |
| Female | 65 (30.8) | 74 (35.2) | 61 (30.0) | 75 (30.0) | 71 (27.3) |
| BMI (kg/m2) | 29.7 ± 4.4 | 29.1 ± 4.7 | 29.3 ± 4.9 | 29.3 ± 5.0 | 29.6 ± 5.0 |
| Insulin-treated diabetes | 70 (33.2) | 76 (36.2) | 74 (36.5) | 87 (34.8) | 95 (36.5) |
| Current smoker | 46/201 (22.9) | 51/201 (25.4) | 39/195 (20.0) | 71/243 (29.2) | 55/253 (21.7) |
| Hypertension | 146 (69.2) | 144 (68.6) | 133 (65.5) | 188/247 (76.1) | 192/259 (74.1) |
| Hypercholesterolemia | 109 (51.7) | 110 (52.4) | 102 (50.2) | 154/245 (62.9) | 164/256 (64.1) |
| Chronic renal failure⁎ | 18 (8.5) | 17 (8.1) | 7 (3.4) | 31 (12.4) | 29 (11.2) |
| Peripheral vascular disease | 20 (9.5) | 28 (13.3) | 30 (14.8) | 30 (12.0) | 35/259 (13.5) |
| LVEF <30% | 5 (2.4) | 6 (2.9) | 4 (2.0) | 8/247 (3.2) | 4/257 (1.6) |
| Previous MI | 54 (25.6) | 55 (26.2) | 40 (19.7) | 56 (22.4) | 56 (21.5) |
| Previous CVA/TIA | 29 (13.7) | 21 (10.0) | 18 (8.9) | 24 (9.6) | 25 (9.6) |
| Previous PCI | 56 (26.5) | 44 (21.0) | 57 (28.1) | 76 (30.4) | 83 (31.9) |
| Previous CABG | 27 (12.8) | 25 (11.9) | 29 (14.3) | 29 (11.6) | 28 (10.8) |
| Clinical syndrome | |||||
| STEMI | 38 (18.0) | 34 (16.2) | 43 (21.2) | 43 (17.2) | 38 (14.6) |
| NSTEMI | 45 (21.3) | 56 (26.7) | 45 (22.2) | 67 (26.8) | 71 (27.3) |
| Unstable angina | 46 (21.8) | 34 (16.2) | 39 (19.2) | 52 (20.8) | 61 (23.5) |
| Stable angina | 82 (38.9) | 86 (41.0) | 76 (37.4) | 88 (35.2) | 90 (43.6) |
| At least 1 complex lesion | 174 (82.5) | 168 (80.0) | 151 (74.4) | 194 (77.6) | 193 (74.2) |
| At least 1 bifurcated lesion | 74 (35.1) | 87 (41.4) | 74 (36.5) | 94 (37.6) | 108 (41.5) |
| At least 1 severely calcified lesion | 54 (25.6) | 55 (26.2) | 53 (26.1) | 60 (24.0) | 53 (20.4) |
| Direct stenting | 33 (15.6) | 25 (11.9) | 33 (16.3) | 49 (19.6) | 56 (21.5) |
| Postdilation | 167 (79.1) | 168 (80.0) | 152 (74.9) | 176 (70.4) | 168 (64.6) |
| Multivessel treatment | 34 (16.1) | 48 (22.9) | 31(15.3) | 45 (18.0) | 59 (22.7) |
This table presents details of the subgroups of patients with known diabetes in BIO-RESORT and BIONYX.
Data are n (%) or means ± SD. There were no significant differences between groups.
Abbreviations: BMI = body mass index; CABG = coronary artery bypass grafting; CVA = cerebrovascular accident; EES = Synergy everolimus-eluting stent; LVEF = left ventricular ejections fraction; MI = myocardial infarction; NSTEMI = non-ST-segment elevation myocardial infarction; PCI = percutaneous coronary intervention; RI-ZES = Resolute Integrity zotarolimus-eluting stent; RO-ZES = Resolute Onyx zotarolimus-eluting stent; SES = Orsiro sirolimus-eluting stent; STEMI = ST-segment elevation myocardial infarction.
Renal insufficiency was defined as an estimated glomerular filtration rate of less than 30 ml per minute per 1.73 m2 of body-surface area, creatinin ≥130 μmol/L, or the need for dialysis.